However, treatment with abatacept increased the blood levels of LAG3+ cTreg (LAG3+ cells within CD4+CD25+Foxp3+) and LAG3+ uTreg (LAG3+ cells within CD4+CD25-Foxp3+) in treated compared to untreated RA patients (Fig. 1C; P = 0.0414, and Fig. 1D; P = 0.0122, for LAG3+ cTreg and LAG3+ uTreg, respectively). This evidence concerns the gene CD4 and rheumatoid arthritis.